PD-L1 in breast cancer
3 EU-approved indications in breast cancer need a PD-L1 result: pembrolizumab (1st line, advanced), sacituzumab govitecan (1st line, advanced) and atezolizumab (1st line, advanced).
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| PD-L13 | ||||
Tecentriq | IC ≥ 1% | + nab-paclitaxel | 1L advanced | No prior chemotherapy for metastatic disease |
Keytruda | CPS ≥ 10 | + chemotherapy | 1L advanced | No prior chemotherapy for metastatic disease |
Trodelvy | CPS ≥ 10 | + pembrolizumab | 1L advanced | No prior systemic therapy for metastatic disease |
See also
Label wording3
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Pembrolizumab (Keytruda)
KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease (see section 5.1).
- Sacituzumab govitecan (Trodelvy)
in combination with pembrolizumab, for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumours express PD-L1 with a combined positive score (CPS) ≥ 10 (see sections 4.2 and 5.1).
- Atezolizumab (Tecentriq)
Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.